

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form SC 13D/A

REGENERON PHARMACEUTICALS INC
Form SC 13D/A
February 11, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934*
(Amendment No. 6)

Regeneron Pharmaceuticals, Inc.

(Name of The Company)

Common Stock (Par Value \$ 0.001 Per Share)

(Title of Class of Securities)

75886F 10 7

(CUSIP Number)

Chris Walther

The Procter & Gamble Company
One Procter & Gamble Plaza
Cincinnati, OH 45202-3315
(513) 983-4463
(Name, Address and Telephone Number of Persons Authorized
to Receive Notices and Communications)

June 10, 2003

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box .

*The remainder of this cover page will be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page will not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but will be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form SC 13D/A

CUSIP No. 75886F 10 7

1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
The Procter & Gamble Company
Identification Number 31-0411980

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
(b)

3 SEC USE ONLY

4 SOURCE OF FUNDS
WC

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION
Ohio

NUMBER OF	7	SOLE VOTING POWER
SHARES		0
BENEFICIALLY	8	SHARED VOTING POWER
OWNED BY		573,630
EACH	9	SOLE DISPOSITIVE POWER
REPORTING		0
PERSON	10	SHARED DISPOSITIVE POWER
		573,630

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
573,630

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
1.1%

14 TYPE OF REPORTING PERSON
CO

SCHEDULE 13D

CUSIP No. 75886F 10 7

1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Procter & Gamble Pharmaceuticals, Inc.

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form SC 13D/A

Identification Number 31-1209457

- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
(b)

3 SEC USE ONLY

4 SOURCE OF FUNDS

WC

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Ohio

NUMBER OF	7	SOLE VOTING POWER
SHARES		0
BENEFICIALLY	8	SHARED VOTING POWER
OWNED BY		573,630
EACH	9	SOLE DISPOSITIVE POWER
REPORTING		0
PERSON	10	SHARED DISPOSITIVE POWER
		573,630

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
573,630

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
1.1%

14 TYPE OF REPORTING PERSON

CO

ITEM 1. SECURITY AND ISSUER.

This Amendment No. 6 ("Amendment No. 6") to the Statement on Schedule 13D (the Statement as so amended, the "Statement") relates to the Common Stock, par value \$.001 per share (the "Common Stock") of Regeneron Pharmaceuticals, Inc., a New York corporation (the "Company"). The principal executive offices of the Company are at 777 Old Saw Mill Road, Tarrytown, NY 10591.

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form SC 13D/A

ITEM 2. IDENTITY AND BACKGROUND.

-
- (a) Name: The Procter & Gamble Company
State of Incorporation: Ohio
Principal Business: Manufacture and marketing of consumer products
Address of Principal Business: One Procter & Gamble Plaza
Cincinnati, Ohio 45202
Name: Procter & Gamble Pharmaceuticals, Inc.
State of Incorporation: Ohio
Principal Business: Manufacture and marketing of pharmaceutical products
Address of Principal Business: same

The Procter & Gamble Company ("P&G") and Procter & Gamble Pharmaceuticals, Inc. ("P&G Pharmaceuticals") are hereinafter referred to collectively as the "Reporting Persons".

- (b) Not applicable
- (c) Not applicable
- (d) Not applicable
- (e) Not applicable
- (f) Not applicable

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

Not applicable

ITEM 4. PURPOSE OF TRANSACTION.

(a) Item 4(a) of the Statement is hereby amended as follows:
Between November 20, 2001 and June 10, 2003, P&G Pharmaceuticals conducted open market sales of the Company's Common Stock (the "Sales") on the dates and in the amounts set forth in Exhibit 1 hereto (the "Schedule of Sales").

- (b) None
- (c) None
- (d) None
- (e) None
- (f) None
- (g) None
- (h) None
- (i) None
- (j) None

ITEM 5. INTERESTS IN SECURITIES OF THE COMPANY.

(a) After giving effect to the Sales, the Reporting Person beneficially owns 573,630 shares of Common Stock, representing 1.1% of the total shares of Common Stock based upon the total number shares of Common Stock outstanding reported in the Company's Form 10-Q filed on November 12, 2003. Because the Reporting Persons beneficially owns less than five percent of the total shares of Common Stock outstanding, this amendment constitutes

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form SC 13D/A

the final amendment to the Statement with respect to the Reporting Persons.

(b) The Reporting Persons share the power to vote or direct the vote and to dispose or to direct the disposition of the shares of Common Stock beneficially owned by such Reporting Person as indicated above.

(c) See Item 4(a) for information responsive to this item.

(d) Not applicable.

(e) The Reporting Persons ceased to be the beneficial owners of five percent of the Company's Common Stock on August 23, 2002. As such, following the date of the filing of this Amendment No. 6, the Reporting Persons will no longer report their ownership interest in the Common Stock of the Company unless and until the Reporting Persons would be required to do so pursuant to Rule 13d-1(a).

ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE COMPANY.

Not applicable

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.

The following documents are filed as Exhibits:

Exhibit 1: Schedule of Sales

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 11, 2004

THE PROCTER & GAMBLE COMPANY

By: /s/ Chris Walther

Name: Chris Walther
Title: Assistant Secretary

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 11, 2004

PROCTER & GAMBLE PHARMACEUTICALS, INC.

By: /s/ Chris Walther

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form SC 13D/A

Name: Chris Walther
 Title: Assistant Secretary

EXHIBIT 1

Schedule of Sales

Date of Sale -----	Number of shares sold -----	Price per Share (\$) -----	Where and How Transaction -----
April 16, 2002	40,000	24.12	Dealer Transaction on the
April, 17, 2002	3,000	24.18	Dealer Transaction on the
April 19, 2002	10,500	24.00	Dealer Transaction on the
July 31, 2002	50,000	17.56	Dealer Transaction on the
August 9, 2002	36,000	17.02	Dealer Transaction on the
August 15, 2002	61,500	17.09	Dealer Transaction on the
August 16, 2002	44,500	17.01	Dealer Transaction on the
August 22, 2002	100,000	17.36	Dealer Transaction on the
August 23, 2002	58,500	17.00	Dealer Transaction on the
October 3, 2002	3,650	15.03	Dealer Transaction on the
December 10, 2002	40,000	20.42	Dealer Transaction on the
June 4, 2003	183,300	14.52	Dealer Transaction on the
June 5, 2003	275,500	15.10	Dealer Transaction on the
June 6, 2003	243,550	15.94	Dealer Transaction on the
June 9, 2003	571,667	16.11	Dealer Transaction on the
June 10, 2003	367,208	16.26	Dealer Transaction on the